A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Summary

This is a multicenter, randomized, open-label phase II clinical trial to evaluate alprostadil liposomal injection in the prevention of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention.

Timeline

Start

2022-10-20

Primary completion

2023-12-04

Completion

2024-01-03

Drugs

Indications